Company Overview
Snapshot
Founded in April 2021 by Yuval Tabach, caVos Biotherapeutics operates with 1–10 employees. The company has raised $3.3M across two funding rounds from six investors. In May 2026, caVos Biotherapeutics was recognized as one of the Most Innovative Life Science Startups at Biomed Israel.
Business overview
caVos Biotherapeutics is a Health Tech & Life Sciences company focused on developing novel anti-cancer drugs. The company utilizes a multi-level genomic algorithm to identify the genetic basis of extraordinary cancer resistance observed in various animals. By leveraging advanced data and genomics, caVos Biotherapeutics aims to uncover existing anti-cancer mechanisms and novel drug targets, thereby revolutionizing drug discovery and identification within the pharmaceutical and drug development sectors.
Strategic signal
In May 2026, caVos Biotherapeutics was awarded as one of the Most Innovative Life Science Startups at Biomed Israel. This recognition highlights the company's innovative approach to drug discovery and validates its potential to significantly impact the pharmaceutical industry by identifying new anti-cancer mechanisms and drug targets.
Log in to access full profile ›Company Intelligence Q&A
- When was caVos Biotherapeutics founded?
- caVos Biotherapeutics was founded in April 2021.
- Who is a founder of caVos Biotherapeutics?
- Yuval Tabach is a founder of caVos Biotherapeutics.
- What is caVos Biotherapeutics' primary focus?
- caVos Biotherapeutics focuses on developing novel anti-cancer drugs by using a multi-level genomic algorithm to uncover genetic bases of cancer resistance in animals.
- What was a significant recent achievement for caVos Biotherapeutics?
- In May 2026, caVos Biotherapeutics was awarded as one of the Most Innovative Life Science Startups at Biomed Israel.
- Which investors participated in caVos Biotherapeutics' November 2024 funding round?
- In November 2024, caVos Biotherapeutics received funding from investors including Entrée Capital and Alumni Ventures.